Dr. Shirish Gadgeel, professor and vice chair, shares his perspective on what drives him professionally and personally.
July 28, 2026
Shirish M. Gadgeel, MBBS, FASCO, is a professor and vice chair for clinical research in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He is also a physician and board-certified thoracic oncologist specializing in the treatment of lung cancer and mesothelioma at Winship Cancer Institute of Emory University. An active member of several professional associations, Dr. Gadgeel serves on the Career Development Committee for the International Association for the Study of Lung Cancer and as a member of the Scientific Advisory Board of ALK Positive.
Over the past 25 years, Dr. Gadgeel’s work has focused on drug development in lung cancer through participation in clinical trials, including investigator-initiated and industry-sponsored studies. While that remains a key research interest, his current focus is on better understanding the biological processes underlying the heterogeneity of responses to novel agents, specifically the impact of the tumor microenvironment, tumor metabolism and signaling pathways beyond primary driver genetic alterations. He is also interested in evaluating biomarkers that enable more precise, individualized treatment.
Recently, Dr. Gadgeel shared his perspective on what drives him professionally and personally.
What is the most rewarding part of your career?
I have enjoyed the relationships and human connections with my patients and their family members.
Can you share an example of where you've seen your research really benefit a patient?
I have had the privilege of being involved in Phase 1, 2 and 3 clinical trials of alectinib for the treatment of ALK-positive lung cancer, as well as the combination of chemotherapy and pembrolizumab for advanced non-squamous non-small cell lung cancer. The results of these clinical trials led to U.S. Food and Drug Administration approval of these treatments. Engaging in all phases of clinical development of these agents, witnessing improvements in the lives of patients with lung cancer and then prescribing these agents as standard-of-care treatments has been extremely gratifying.
What are some major goals you’re working on this year?
My goals are to collaborate with translational scientists with the intent of developing clinical trials based on concepts developed in the laboratory, collaborate with clinical research leaders at Winship to improve access to clinical trials for patients with cancer, and mentor junior colleagues.
What do you enjoy doing in your free time when you're not at work?
In my free time, I enjoy spending time with my family, taking walks on nature trails and traveling. I am an avid fan of Detroit sports teams and follow them closely.
What are you looking forward to this year?
My oldest son is getting married in September. Following the wedding, my wife, Manisha, and my son, Rahul, will join me in Atlanta. Manisha will also be joining Emory University and working in Dr. Greg Lesinski’s laboratory.